Keybank National Association OH held its stake in MEI Pharma, Inc. (NASDAQ:MEIP) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 57,642 shares of the company’s stock at the close of the second quarter. Keybank National Association OH owned 0.16% of MEI Pharma worth $138,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in MEIP. TFS Capital LLC lifted its stake in MEI Pharma by 91.5% in the first quarter. TFS Capital LLC now owns 75,489 shares of the company’s stock worth $122,000 after acquiring an additional 36,078 shares during the last quarter. Bank of Montreal Can purchased a new position in MEI Pharma in the second quarter worth approximately $126,000. Goldman Sachs Group Inc. lifted its stake in MEI Pharma by 131.7% in the first quarter. Goldman Sachs Group Inc. now owns 80,570 shares of the company’s stock worth $131,000 after acquiring an additional 45,793 shares during the last quarter. Spark Investment Management LLC lifted its stake in MEI Pharma by 119.3% in the second quarter. Spark Investment Management LLC now owns 62,500 shares of the company’s stock worth $149,000 after acquiring an additional 34,000 shares during the last quarter. Finally, Oxford Asset Management purchased a new position in MEI Pharma in the first quarter worth approximately $176,000. Hedge funds and other institutional investors own 18.00% of the company’s stock.

MEIP has been the subject of a number of recent research reports. Cann reiterated an “outperform” rating on shares of MEI Pharma in a research note on Wednesday, May 24th. Oppenheimer Holdings, Inc. initiated coverage on shares of MEI Pharma in a research note on Thursday, May 25th. They issued an “outperform” rating and a $6.50 price target for the company. Finally, Zacks Investment Research upgraded shares of MEI Pharma from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a research note on Wednesday, July 19th.

MEI Pharma, Inc. (NASDAQ:MEIP) opened at 2.75 on Friday. The company has a 50-day moving average of $2.73 and a 200-day moving average of $2.15. The stock has a market cap of $101.58 million, a P/E ratio of 39.29 and a beta of 1.65. MEI Pharma, Inc. has a 52 week low of $1.34 and a 52 week high of $3.26.

MEI Pharma (NASDAQ:MEIP) last issued its quarterly earnings data on Tuesday, September 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. MEI Pharma had a net margin of 11.48% and a return on equity of 5.26%. The company had revenue of $0.45 million during the quarter, compared to the consensus estimate of $0.60 million. On average, analysts predict that MEI Pharma, Inc. will post ($1.15) EPS for the current fiscal year.

WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.dailypolitical.com/2017/09/17/keybank-national-association-oh-holds-holdings-in-mei-pharma-inc-meip.html.

MEI Pharma Profile

MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Institutional Ownership by Quarter for MEI Pharma (NASDAQ:MEIP)

Receive News & Ratings for MEI Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.